Home » Stocks » FGEN

FibroGen, Inc. (FGEN)

Stock Price: $33.59 USD -0.14 (-0.42%)
Updated Mar 5, 2021 11:06 AM EST - Market open
Market Cap 3.25B
Revenue (ttm) 176.32M
Net Income (ttm) -189.29M
Shares Out 89.85M
EPS (ttm) -2.11
PE Ratio n/a
Forward PE 80.65
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $33.59
Previous Close $33.73
Change ($) -0.14
Change (%) -0.42%
Day's Open 33.70
Day's Range 33.31 - 34.50
Day's Volume 327,440
52-Week Range 22.65 - 57.21

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Investors Business Daily - 2 days ago

FibroGen suffered a setback after U.S. regulators requested an additional meeting before reviewing the company's anemia treatment. In response, FGEN stock crashed on Tuesday.

Zacks Investment Research - 3 days ago

FibroGen (FGEN) delivered earnings and revenue surprises of -120.69% and -25.01%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 3 days ago

SAN FRANCISCO, March 01, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN) and its partner, AstraZeneca (LSE/STO/Nasdaq: AZN), today announced that the Cardiovascular and Renal Drugs Advi...

GlobeNewsWire - 3 days ago

• Strong Fourth Quarter China Roxadustat Net Sales of $29.2 Million and 2020 full-year Net Sales of $72.5 Million

Zacks Investment Research - 1 week ago

FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 2 weeks ago

SAN FRANCISCO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2020 financial results on Monday, March 1 after the market close. ...

GlobeNewsWire - 3 weeks ago

SAN FRANCISCO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the followi...

Seeking Alpha - 2 months ago

FibroGen, Inc. is a commercial-stage global biopharmaceutical company developing and commercializing innovative therapeutics treating anemia, fibrotic diseases, and cancer. FibroGen's pipeline...

GlobeNewsWire - 2 months ago

SAN FRANCISCO, Dec. 22, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced dosing of the first patient in the ZEPHYRUS-2 Phase 3 clinical study of pamrevlumab in patients w...

The Motley Fool - 2 months ago

The FDA delivered a discouraging update in time for the holidays.

GlobeNewsWire - 2 months ago

SAN FRANCISCO, Dec. 18, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period of the New Drug A...

GlobeNewsWire - 3 months ago

New data show safety and efficacy of roxadustat in treating anemia secondary to lower-risk myelodysplastic syndrome s (MDS) regardless of ring sideroblast (RS) or baseline e rythro poietin level

Zacks Investment Research - 3 months ago

FibroGen's (FGEN) Evrenzo (roxadustat) wins second approval in Japan for treating anemia caused by chronic kidney disease in non-dialysis-dependent patients.

GlobeNewsWire - 3 months ago

Approval by MHLW provides new HIF-PH inhibitor treatment option for healthcare providers and adult patients with anemia of CKD not on dialysis Approval by MHLW provides new HIF-PH inhibitor tr...

Seeking Alpha - 3 months ago

FibroGen, Inc. (FGEN) CEO Enrique Conterno on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

SAN FRANCISCO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the followi...

Zacks Investment Research - 3 months ago

FibroGen (FGEN) delivered earnings and revenue surprises of 139.33% and -10.19%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 3 months ago

- Strong T hird Quarter China Roxadustat Net Sales of $22.7 M illion - - Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time -

GlobeNewsWire - 4 months ago

SAN FRANCISCO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2020 financial results on Thursday, November 5 after the market close. FibroGen w...

GlobeNewsWire - 4 months ago

In non-dialysis and dialysis-dependent CKD patients, Major Adverse Cardiovascular Event (MACE) and MACE+ incidence rates were lowest when patients achieved hemoglobin levels ≥ 1 0 g/dL

GlobeNewsWire - 4 months ago

Late-breaking abstracts explore cardiovascular outcomes of patients with anemia in chronic kidney disease ( CKD ) treated with roxadustat, including associations with achieved hemoglobin level...

GuruFocus - 4 months ago

A drug from San Francisco-based FibroGen Inc. (NASDAQ:FGEN) is one of five medications the Food and Drug Administration is expected to rule on in the next three months in what BioPharma Dive c...

GlobeNewsWire - 5 months ago

SAN FRANCISCO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced the appointment of Percy Carter, MBA, PhD, to the newly-created position of Chief Scientific Officer...

GlobeNewsWire - 6 months ago

SAN FRANCISCO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced the initiation of LELANTOS, a Phase 3, randomized, double-blind, placebo-controlled trial of pamrevlu...

Seeking Alpha - 6 months ago

FibroGen's (FGEN) CEO Enrique Conterno on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

FibroGen (FGEN) delivered earnings and revenue surprises of -61.02% and 22.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 6 months ago

- Strong Second Quarter China Roxadustat Net Sales of $15.7 million - - Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time -

GlobeNewsWire - 6 months ago

- Appoints Aoife Brennan, M.B., B.Ch., President and CEO of Synlogic Inc. (NASDAQ:SYBX) -- Appoints Ben Cravatt, Ph.D., Professor and the Norton B. Gilula Chair of Chemical Biology in the Depa...

Zacks Investment Research - 7 months ago

FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Forbes - 7 months ago

Have you missed the rally of these 4 stocks in the past three years? HubSpot, Everbridge, FibroGen, and Inphi Corporation have grown more than 100% since the beginning of 2017 despite posting ...

Other stocks mentioned: EVBG, HUBS, IPHI
GlobeNewsWire - 7 months ago

SAN FRANCISCO, July 23, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2020 financial results on Thursday, August 6 after the market close. FibroGen ...

Zacks Investment Research - 8 months ago

FibroGen (FGEN) enrolls the first patient in a placebo-controlled phase II study on pamrevlumab in hospitalized patients with acute COVID-19 infection in the United States.

GlobeNewsWire - 8 months ago

SAN FRANCISCO, June 23, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the initiation of a randomized, double-blind, placebo-controlled Phase 2 Study investigating th...

GlobeNewsWire - 8 months ago

SAN FRANCISCO, June 22, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced the appointment of Thane Wettig to the newly-created position of Chief Commercial Officer, where he w...

Zacks Investment Research - 8 months ago

FibroGen (FGEN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Zacks Investment Research - 8 months ago

FibroGen (FGEN) starts a phase II/III study in Italy on pamrevlumab versus standard of care in patients with severe COVID-19 infection.

GlobeNewsWire - 8 months ago

SAN FRANCISCO, June 08, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) announced data from three roxadustat clinical trials, including the Phase 3 DOLOMITES study evaluating roxadusta...

GlobeNewsWire - 8 months ago

Additional Pamrevlumab Clinical Trials Planned in Patients Hospitalized in United States with Severe COVID-19 Additional Pamrevlumab Clinical Trials Planned in Patients Hospitalized in United ...

GlobeNewsWire - 9 months ago

Submission for the treatment of anemia in adult patients with chronic kidney disease Submission for the treatment of anemia in adult patients with chronic kidney disease

Seeking Alpha - 9 months ago

FibroGen, Inc. (FGEN) CEO Enrique Conterno on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 9 months ago

SAN FRANCISCO, May 08, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will participate in the Bank of America Securities 2020 Health Care Conference that is being held virtually on M...

Zacks Investment Research - 9 months ago

FibroGen (FGEN) delivered earnings and revenue surprises of -196.67% and -64.10%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 9 months ago

FibroGen (FGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 10 months ago

FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 10 months ago

SAN FRANCISCO, April 20, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the United Kingdom’s High Court of Justice has held certain patents1 relating to methods ...

Seeking Alpha - 1 year ago

FibroGen, Inc. (FGEN) CEO Enrique Conterno on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

FibroGen (FGEN) delivered earnings and revenue surprises of -80.65% and -74.01%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 1 year ago

A decision on Roxadustat should arrive by Dec. 20.

Zacks Investment Research - 1 year ago

The FDA accepts FibroGen's (FGEN) NDA for roxadustat for the treatment of anemia of chronic kidney disease in both non-dialysis-dependent and dialysis-dependent patients.

About FGEN

FibroGen, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits ... [Read more...]

Industry
Biotechnology
IPO Date
Nov 14, 2014
CEO
Enrique Conterno
Employees
531
Stock Exchange
NASDAQ
Ticker Symbol
FGEN
Full Company Profile

Financial Performance

In 2020, FibroGen's revenue was $176.32 million, a decrease of -31.28% compared to the previous year's $256.58 million. Losses were -$189.29 million, 145.9% more than in 2019.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for FibroGen stock is "Buy." The 12-month stock price forecast is 54.56, which is an increase of 62.43% from the latest price.

Price Target
$54.56
(62.43% upside)
Analyst Consensus: Buy